Products & Services

Predictive Biology + Relevant Assays = Safe Drugs

Leveraging Cellular Dynamics International’s technology platform, scientists have made significant advances in accurately predicting cardiotoxicity. The foundation of these improvements lie in the use of iCell® Cardiomyocytes and the newly launched iCell Cardiomyocytes2. These human cardiomyocytes are being coupled with existing and novel platforms to perform early, robust, and predictive assessments of cardiotoxicity.

Complete and submit the form below to access the following case studies and get started with early, predictive, and easy to implement cardiotoxicity testing.

SOT 2015 Symposium Presentation:

Use of Human-induced Pluripotent Stem Cell-derived Cardiomyocytes As a Screen for Drug-induced Cardiotoxicity 

Overview of on- and off-target cardiotoxicity detection research using iPSC-derived cardiomyocytes

(Presenter: Kyle Kolaja, PhD, DABT Fellow, ATS, Cellular Dynamics International)


SOT 2015 Workshop Presentation:

Unraveling Kinase Inhibitor Cardiotoxicity with Cardiomyocyte Impedance Assays

Overview of the development validation of methodology to effectively unravel and predict kinase inhibitor toxicity

(Presenter: Sarah Lamore, PhD, Senior Scientist, Discovery Safety, AstraZeneca Pharmaceuticals)


New Product Information:

iCell Cardiomyocytes2

These cells offer all the robust, predictive advantages of iCell Cardiomyocytes with the additional benefit of being ready to use in less than half the culture time.


Access Case Studies